Cellectis therapeutics
8 rue de la Croix Jarry
75013 Paris / FRANCE
Phone : +33 (0)1 81 69 16 02
Fax : +33 (0)1 81 69 16 08
Cellectis therapeutics
Cellectis therapeutics aims to treat patients suffering from serious diseases that are resistant to conventional therapy and to fulfill unmet medical needs in the fields of cancer, viral infections and genetic diseases. Cellectis therapeutics’ treatment paradigm is based on the use of in-house developed nucleases that specifically target relevant genomic sequences. This technology can be used in a variety of applications including the correction of a genetic defect in the patient’s genome, the destruction of viral genomes or the inactivation of genes in order to create cells with modified characteristics. This therapeutic approach addresses the cause of a disease, rather than merely treating its symptoms.
Dr Mathieu Simon joined Cellectis on April 2nd this year as Senior vice-president of the Group. After a high-level international carrier in the pharmaceutical field, in large groups such as Wyeth, he took in charge the development of Cellectis’s therapeutic activities and will soon be nominated president of each of the dedicated subsidiaries, Cellectis therapeutics included.
Our mission: Innovative strategies for the development of wide-reaching therapeutic treatments
Cellectis therapeutics has ongoing projects in monogenetic diseases (e.g. myopathies, hemoglobinopathies, hemophilia), as well as a continuing anti-viral program for the prevention of recurrent Herpes virus (HSV-1) infection...